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The PRH (proline-rich homeodomain) [also known as Hex (hae-
matopoietically expressed homeobox)] protein is a transcription
factor that functions as an important regulator of vertebrate
development and many other processes in the adult including
haematopoiesis. The Groucho/TLE (transducin-like enhancer)
family of co-repressor proteins also regulate development and
modulate the activity of many DNA-binding transcription factors
during a range of diverse cellular processes including haemato-
poiesis. We have shown previously that PRH is a repressor of tran-
scription in haematopoietic cells and that an Eh-1 (Engrailed
homology) motif present within the N-terminal transcription
repression domain of PRH mediates binding to Groucho/TLE pro-
teins and enables co-repression. In the present study we demon-
strate that PRH regulates the nuclear retention of TLE proteins
during cellular fractionation. We show that transcriptional
repression and the nuclear retention of TLE proteins requires
PRH to bind to both TLE and DNA. In addition, we characterize
a trans-dominant-negative PRH protein that inhibits wild-type
PRH activity by sequestering TLE proteins to specific subnuclear
domains. These results demonstrate that transcriptional repression
by PRH is dependent on TLE availability and suggest that sub-
nuclear localization of TLE plays an important role in transcrip-
tional repression by PRH.
Key words: co-repressor, Groucho, haematopoiesis, haematopoi-
etically expressed homeobox (Hex), nuclear retention, pro-
line-rich homeodomain (PRH), transcriptional repression, trans-
dominant negative, transducin-like enhancer (TLE).
INTRODUCTION
Transcription factors that bind to DNA are important regulators
of multiple processes in the cell and often act in conjunction with
non-DNA-binding co-repressors and co-activators to bring about
changes in gene expression. Generally the role of the co-regulat-
ory proteins is to recruit chromatin remodelling enzymes or chro-
matin-binding proteins in order to set up more open or closed
chromatin configurations. Most co-activators and co-repressors
are able to interact with a variety of DNA-bound factors to
regulate gene expression. The PRH (proline-rich homeodomain)
[also known as Hex (haematopoietically expressed homeobox)]
protein is a DNA-binding transcription factor that can regulate
gene expression in a number of tissues using multiple mechanisms
(reviewed in [1]). PRH forms oligomers in cells and can bind to
DNA in the oligomeric state [2]. When bound to DNA, PRH
generally functions as a repressor of transcription [3–6] and we
have shown previously that PRH can recruit members of the
Groucho/TLE (transducin-like enhancer) family of co-repressor
proteins [7]; however, in some contexts, PRH functions as a
DNA-bound activator of transcription [8]. PRH can also regulate
transcription without binding to DNA by regulating the activity of
other DNA-binding transcription factors [9–11]. In addition, PRH
can regulate gene expression post-transcriptionally by regulating
the transport of specific mRNAs from the nucleus to the cytoplasm
[12].
PRH regulates embryonic development in all vertebrates and is
necessary for the development of embryonic forebrain, thyroid,
lungs, liver and heart [13–15]. PRH also plays a role in the early
development of vascular tissues and the formation of haema-
topoietic lineages [13,16–20]. In the adult, PRH is expressed in
thyroid, liver and lungs [21] and may play a role in the main-
tenance of differentiation of these tissues. Moreover this protein
regulates haematopoiesis in the embryo and in the adult
[13,22]. PRH is strongly expressed in pluripotent haematopoietic
progenitors, in erythromyeloid and B-cell progenitors, but not
in T-cell lineages [20,23–25]. In general, the gradual down-
regulation of PRH is associated with differentiation of most
haematopoietic lineages [24,26]. PRH interacts with the growth
control proteins PML (promyelocytic leukaemic) and translation
initiation factor eIF-4E (eukaryotic initiation factor 4E) [27],
and has been shown to regulate cell growth or differentiation
in haematopoietic cells as well as in a number of different
tissues [16,28,29]. Decreased PRH expression and loss of nuclear
localization of PRH is implicated in a number of human myeloid
leukaemias [30,31]. In addition, a chromosomal translocation
resulting in a PRH fusion protein that can activate transcription
and has trans-dominant-negative activity over wild-type PRH has
been shown to be a causative agent in acute myeloid leukaemia
[32].
The PRH protein consists of three regions: a proline-rich N-
terminal domain, a central homeodomain and an acidic C-terminal
domain. The proline-rich N-terminal domain of PRH can make
multiple protein–protein interactions and binds to several proteins
including PML [27], eIF-4E [12], proteosome subunit HC8 [33]
and members of the Groucho/TLE [7] family of co-repressor pro-
teins. PRH forms foci in haematopoietic cells and exists as oligo-
meric complexes in vivo and in vitro [2]. The N-terminal domain
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of PRH is required for oligomerization and transcriptional re-
pression and can influence the DNA-binding activity of the PRH
homeodomain [2,34]. As well as binding to DNA [6], the
PRH homeodomain is important in PRH oligomerization [2] and
forms protein–protein interactions with other transcription factors
[11]. The C-terminal domain of PRH is rich in acidic residues
but appears to play no role in repression [6]; however, both the
homeodomain and C-terminal domain are reported to play a role
in transcription activation by PRH [35].
The TLE proteins are members of a family of transcription
co-repressors that includes the archetypical Drosophila protein
Groucho. Like PRH, Groucho/TLE family proteins are involved in
many developmental decisions including: neuronal and epithelial
cell differentiation, segmentation and sex determination, and the
differentiation of haematopoietic, osteoblast and pituitary cells
[36–40]. Members of the Groucho/TLE family do not have DNA-
binding activity, but are instead recruited to DNA by interactions
with DNA-binding proteins. Once recruited to a promoter, these
proteins can bring about long-range transcriptional repression
by recruiting histone deacetylases [41–43] and by interacting
directly with histones [44]. TLE proteins form tetramers and
larger oligomeric complexes and oligomerization is essential for
co-repression [45,46]. The TLE proteins are phosphoproteins and
are hyperphosphorylated during the cell cycle and during cell
differentiation [45,47,48]. A subset of the DNA-binding transcrip-
tion factors that interact with Groucho/TLE proteins in the
haematopoietic compartment, including Hes1, Runx-1 and Pax5,
have been shown to play a role in regulating TLE phosphorylation
and modulating its activity [49,50]. For example, Hes1- and Runx-
1-dependent phosphorylation of nuclear TLE1 by CK2 (casein
kinase 2) has been shown to increase its co-repressor activity and
its association with chromatin [49]. In contrast, phosphorylation
of TLE by HIPK2 (homeodomain interacting protein kinase 2)
decreases its co-repression ability [51].
We have shown previously that endogenous PRH and TLE are
present in both the cytoplasmic and the nuclear compartments
of K562 cells [7]. We have also shown that a short sequence of
amino acids in the PRH N-terminal domain, known as the Eh-1
(Engrailed homology) motif, mediates the binding of PRH to
TLE proteins. Moreover we have demonstrated that a direct
interaction between TLE1 and PRH is required for co-repression
of transcription [7]. In the present study, we demonstrate that
PRH brings about nuclear retention of endogenous TLE proteins
in early myeloid progenitors (K562 cells). Furthermore we show
that a mutated form of PRH that is defective in DNA binding
can function as a trans-dominant negative of wild-type PRH by
sequestering TLE proteins.
EXPERIMENTAL
Mammalian expression and reporter plasmids
The mammalian expression plasmid pMUG1-Myc–PRH ex-
presses Myc-tagged human PRH (amino acids 7–270). pMUG1-
Myc–PRH and pMUG1-Myc–PRHF32E have been described
previously [7]. A QuikChange® kit (Stratagene) was used accord-
ing to the manufacturer’s protocol for the mutagenesis of pMUG1-
Myc–PRH to produce pMUG1-Myc–PRH R188A, R189A
and pMUG1-Myc–PRH N187A, and for the mutagenesis of
pMUG1-Myc–PRH F32E to produce pMUG1-Myc–PRH F32E/
R188A,R189AandpMUG1-Myc–PRH F32E/N187A.The result-
ing mutants were fully sequenced to confirm the sequence change.
pcDNA3-Myc–PRH-HD 130–198 was created by cloning a
BamHI-EcoRI fragment encoding the PRH homeodomain (amino
acids 130–198 followed by an in-frame stop) into the pcDNA3
vector (Invitrogen). The fragment was generated using PCR and
a 5′ primer that contains the Myc epitope (the Myc tag is under-
lined): the 5′ primer is 5′-CGGGAATCCATGGAACAAAAA-
CTCATCTCAGAAGAGGATCTGTTGCAGAGGCCTCTGCA-
TAAAAGG-3′ and the 3′ primer is 5′-AGAGAATTCCTACTC-
CTGTTTTAGTCTCCTCCA-3′. The GFP (green fluorescent pro-
tein)–PRH plasmid was constructed by inserting the PRH cDNA
from a BlueScipt clone into the EcoRI and KpnI sites of eGFPc1
(Clontech).
The pTK (thymidine kinase promoter)–PRH reporter plasmid
has been described previously [6]. The pSV-β-galactosidase
control vector (pSV-lacZ) was obtained from Promega. The mam-
malian expression plasmid pCMV2-FLAG–TLE1 contains the
TLE1 coding sequence in-frame with the FLAG epitope [7].
Bacterial expression plasmids
The plasmid pTrcHisA-hPRH expresses recombinant full-
length histidine-tagged and Myc-tagged human PRH7−270 in
bacteria and has been described previously [2]. pTrcHisA-
PRH-hHD expresses a histidine-tagged truncated PRH construct
consisting of the human PRH homeodomain. This construct was
generated by cloning a PCR fragment carrying the PRH human
homeodomain (amino acids 130–198 followed by an in-frame
stop) between the XhoI and EcoRI sites of pTrcHisA using the
primers 5′-AGACTCGAGTTGCAGAGGCCTCTGCATAAAA-
GG-3′ and 5′-AGAGAATTCCTACTCCTGTTTTAGTCTCCTC-
CA-3′ (the restriction sites are underlined). The expres-
sion plasmids pTrcHisA-Myc–PRHF32E, pTrcHisA-Myc–PRH
R188A,R189A, pTrcHisA-Myc–PRH N187A, pTrcHisA-Myc–
PRH F32E/R188A,R189A and pTrcHisA-Myc–PRH F32E/
N187A were created by cloning BamHI-EcoRI fragments
encoding the mutated human PRH cDNAs from the corresponding
pMUG1 series of plasmids (described above) into pTrcHisA.
Expression and purification of tagged-PRH proteins
The His–PRH fusion proteins were expressed in BL21 pLysS cells
(Novagen). Fusion protein expression was induced with 1 mM
IPTG (isopropyl β-D-thiogalactoside). Cells were harvested after
4 h at 37 ◦C, resuspended in lysis buffer [100 mM phosphate buffer
(pH 7.4), 300 mM NaCl, 10 mM imidazole, 5 μg/ml DNase and
10 μg/ml RNase) and lysed by the addition of 100 μl of lysozyme
(1 mg/ml) for 20 min, followed by four bursts of sonication at
60% amplitude. After centrifugation for 30 min at 39000 g in
ss34 rotor (Sorval RC-3B) the His–PRH fusion proteins contained
in the supernatant were purified over a HiTrap chelating column
charged with nickel ions (1 ml, Amersham Pharmacia Biotech)
using an ¨AKTA FPLC system and UNICORN 3.10 software.
Proteins were eluted with a 250 mM imidazole buffer. Aliquots of
these proteins were assayed for purity by SDS/PAGE followed by
staining with Coomassie Blue. Proteins were quantified using the
Bio-Rad phosphoric acid protein assay and were stored at −80 ◦C
after dialysis into PBS containing 20% glycerol.
EMSA (electrophoretic mobility-shift assay)
A double-stranded oligonucleotide carrying a PRH-binding site
was produced by heating the complementary single-stranded
oligonucleotides shown below at 90 ◦C for 1 min and then slow
cooling to 20 ◦C: 5′-GCTTCTGGGAAGCAATTAAAAAATGG-
CTCGAGCT-3′ and 3′-AGACCCTTCGTTAATTTTTTACCGA-
GC-5′.
This oligonucleotide (400 ng) was labelled with [α-32P]dATP
using Klenow enzyme at 30 ◦C for 30 min. Unincorporated [α-32P]-
dATP was then removed using a Micro Bio-Spin 6 column
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(Bio-Rad). The labelled oligonucleotide (100 pM) was incubated
with purified His-tagged proteins in 20 mM Tris/HCl (pH 8.0),
50 mM NaCl, 1 mM MgCl2, 1 mM DTT (dithiothreitol), 80 ng/ml
poly(dI-dC) · (dI-dC), 0.5 mg/ml BSA and 10% glycerol at 4 ◦C
for 30 min. Free and bound DNA was then separated on 6% non-
denaturing polyacrylamide gels run in 0.5 × TBE (1 × TBE =
45 mM Tris/borate and 1 mM EDTA) and quantified using a
PhosphoImager with Molecular Dynamics ImageQuant software
(version 3.3). All experiments were repeated three times.
Cell culture and transfection assays
K562 cells were maintained in DMEM (Dulbecco’s modified
Eagle’s medium) supplemented with 10% FCS (foetal calf
serum), 100 units/ml penicillin and 0.1 mg/ml streptomycin at
37 ◦C in an atmosphere of 5% CO2, 20% O2 and 80% N2.
For transient-transfection assays, cells were transferred to 0.4 cm
electroporation cuvettes at a density of 1 × 107 cells in 200 μl of
medium. The cells and 5 μg of the luciferase reporter plasmid
and 5 μg of the β-galactosidase reporter plasmid were mixed by
pipetting and were electroporated at 250 V, 975 μF. In repression
experiments, the cells were co-transfected with either pMUG1
vector or the pMUG1-Myc–PRH series of plasmids as detailed
in the Results section below. Electroporated cells were incubated
for 24 h as described above. The cells were then harvested by
centrifugation [1800 g for 5 min at room temperature (24 ◦C)] and
the luciferase activity was assayed using the Promega Luciferase
Assay System according to the manufacturer’s protocol. A β-
galactosidase assay was performed as an internal control for
transfection efficiency: 40 μl of cell lysate was mixed with
900 μl of Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM
KCl, 1 mM MgSO4 and 50 mM 2-mercaptoethanol) and 200 μl
of ONPG (o-nitrophenyl β-D-galactopyranoside; 4 mg/ml) and
incubated at 37 ◦C for at 1 h. The reaction was stopped by adding
200 μl of 1 M Na2CO3 and the absorbance was measured at
420 nm. After subtraction of the background, the luciferase counts
were normalized against the β-galactosidase value.
Whole-cell extracts and cell fractionation
Whole-cell extracts from 2 × 107 K562 cells were made as
follows. The cell pellet was collected by centrifugation for 5 min
at 1800 g in a Centurion bench-top centrifuge. The cell pellet was
washed twice in PBS and then resuspended in 400 μl of lysis
buffer [150 mM NaCl, 50 mM Tris/HCl (pH 7.5), 0.1% SDS and
0.1%Nonidet P40]. The cell suspension was drawn up and down
six times through a 3 × Monojet needle (1.1 mm × 50 mm, 19G ×
2”), incubated on ice for 20 min, and then centrifuged at maximum
speed for 15 min at 4 ◦C in a microcentrifuge.
Nuclear and post-nuclear extracts were made as follows:
2 × 107 K562 cells were centrifuged at 1800 g in a Centurion
bench-top centrifuge (IEC Centra 4B) and the pellet was resus-
pended in 200 μl of buffer [20 mM Tris/HCl (pH 7.5), 5 mM
MgCl2 and 1 mM DTT containing protease inhibitor cocktail
(Sigma)] at 4 ◦C for 10 min. Then, 15 μl of 10% (v/v) Nonidet
P40 was added to the lysate and mixed by vortexing. The lysate
was centrifuged for 1 min at 16000 g in a microcentrifuge and
the supernatant was removed and stored at −80 ◦C as the soluble
post-nuclear fraction. The nuclei in the pellet were resuspended
in 200 μl of 50 mM Tris/HCl (pH 7.5), 500 mM NaCl, 1%
(v/v) Nonidet P40 and 0.1% SDS, containing protease inhibitor
cocktail (Roche) for 20 min at 4 ◦C and then centrifuged for 1 min
at 16000 g at 4 ◦C in a microcentrifuge. The supernatant was
removed and stored at −80 ◦C as the soluble nuclear extract.
Phosphatase experiments
CIP (calf intestinal phosphatase) and CIP buffer was obtained
from (Fermentas). K562 nuclear extracts prepared from cells
expressing Myc–PRH were incubated with a cocktail of phosphat-
ase inhibitors in CIP buffer for 30 min at 4 ◦C or 37 ◦C. The phos-
phatase inhibitor cocktail contained 50 mM NaF, 1 mM Na3VO4,
10 mM sodium β-glycerophosphate, 1 mM EDTA and 5 mM
sodium pyrophosphate). CIP (1 or 2 μl) was added to nuclear
extracts either containing phosphatase inhibitors or without phos-
phatase inhibitors for 30 min at 37 ◦C.
Co-immunopreciptitation assays
K562 cells (2 × 107) were co-transfected with pCMV2-FLAG–
TLE1 and either pMUG1-Myc-PRH or one of the pMUG1-Myc–
PRH derivatives as described above. Whole-cell extracts were
prepared by resuspending the cell pellet into 150 μl of lysis buffer
[50 mM Tris/HCl (pH 8), 100 mM NaCl, 20 mM NaF, 10 mM
KH2PO4, 1 mM DTT, 1% (v/v) Triton and 10% glycerol] for
30 min at 4 ◦C. An equivalent volume of binding buffer [50 mM
Tris/HCl (pH 8), 100 mM KCl, 0.1 mM EDTA, 2 mM DTT, 0.2%
Nonidet P40, 0.1% BSA and 2.5% glycerol] was added to
the lysate before incubation with a monoclonal anti-Myc9E10
antibody (Santa Cruz Biotechnology) for 1 h at 4 ◦C under
agitation. Protein G beads (Sigma) were then washed with the
binding buffer and incubated with the extracts for a further 2 h at
4 ◦C. After this time, the beads were collected by centrifugation in
an Eppendorf microcentrifuge (16000 g for 1 min), washed three
times in 1 ml of buffer [50 mM Tris/HCl (pH 8), 200 mM NaCl,
2 mM DTT and 0.5% Nonidet P40], and then resuspended in
SDS-loading buffer. All operations were carried out at 4 ◦C and
in the presence of protease inhibitor cocktail (Sigma). After SDS/
PAGE, the proteins were immunoblotted on to Immobilon-P mem-
brane, and tagged TLE1 and PRH were detected using an anti-
FLAG antibody (Sigma) and anti-Myc9E10 antibody respectively.
Western blot analysis
Post-nuclear and nuclear fractions were collected as described
above and separated by SDS/PAGE. Immunoblot analyses were
performed using appropriate antibodies to detect endogenous
PRH (mouse polyclonal antibody, [6,26]), Myc-tagged PRH
(mouse anti-Myc9E10 antibody), endogenous TLE proteins (pan-
TLE goat polyclonal sc13373; Santa Cruz Biotechnology),
FLAG-tagged TLE1 (rabbit anti-FLAG polyclonal antibody;
Sigma), HC8 (mouse monoclonal antibody; Affiniti), tubulin
(mouse monoclonal MS-581-P1; NeoMarkers) and lamin A/C
(rabbit polyclonal sc-20688; Santa Cruz Biotechnology).
Immunofluorescence
K562 cells were adhered to coverslips coated with poly-lysine.
After washing in PBS the cells were fixed by incubating the cover-
slips with 4% (w/v) parafomaldehyde for 30 min. The cells
were then rinsed with PBS and incubated with PBSA [3% (v/v)
donkey serum in PBS] for 40 min to block non-specific antibody
binding. After rinsing in PBS, antibody staining was performed
for 1 h with an optimized dilution for each different antibody
used either alone or in combination [rabbit anti-FLAG polyclonal
antibody (Sigma) 1:200 and/or a mouse anti-Myc9E10 antibody
(Santa Cruz Biotechnology) 1:50]. The cells were then rinsed
twice in PBS and incubated with secondary antibodies for 1 h at
22 ◦C. PRH and TLE1 were detected with a TRITC (tetramethyl-
rhodamine β-isothiocyanate) donkey anti-mouse secondary anti-
body (Stratec) and an Alexa Fluor® 488-labelled donkey anti-rab-
bit secondary antibody (Molecular Probes) respectively, both
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at a 1:100 dilution. The coverslips were mounted on slides
with DAPI (4′,6-diamidino-2-phenylindole)-containing mounting
medium (Vectashield) and immunostained cells were viewed on
a Leica DM IRBE confocal microscope. Imaging was performed
using Leica Confocal Software Version 2.00.
RESULTS
PRH increases the retention of TLE proteins within the nucleus
To determine whether PRH alters the subcellular localization of
TLE in haematopoietic cells, we transfected K562 cells with plas-
mids expressing pFLAG–TLE1 alone or pFLAG–TLE1 together
with GFP or GFP–PRH. We examined the subcellular localization
of these proteins using immunofluorescent staining and confocal
microscopy. A TRITC-labelled anti-FLAG antibody was used
to detect FLAG–TLE1, the intrinsic fluorescence of the GFP
proteins was used to detect GFP and GFP–PRH, and DAPI was
used to detect DNA. Results from representative transfected cells
are shown in Figure 1(A). When expressed alone FLAG–TLE1
(red) was present in the cytoplasm and nucleus of K562 cells
(Figure 1A, middle left-hand panel); however co-expression with
GFP–PRH resulted in the majority of FLAG–TLE1 appearing in
the nucleus (Figure 1A, middle panel), whereas co-expression
with GFP resulted in the majority of TLE1 remaining in the
cytoplasm (Figure 1A, middle right-hand panel). This experiment
was repeated using a Myc-tagged PRH protein to rule out any
effects of the GFP tag on PRH activity. Immunofluorescence
results from representative transfected cells are shown in Fig-
ure 1(B). In the absence of Myc–PRH, FLAG–TLE1 (green) was
present in the nucleus, but was predominantly present in the
cytoplasm of K562 cells. Co-expression of Myc–PRH with
FLAG–TLE1 resulted in the majority of TLE1 appearing in
the nucleus (Figure 1A, middle right-hand panel) together with
Myc–PRH (Figure 1A, bottom right-hand panel). Taken together
these results suggest that PRH influences the localization of TLE
proteins in the cell.
To examine whether endogenous TLE proteins are also retained
in the nucleus by expression of Myc–PRH we first examined the
subcellular localization of TLE proteins using immunofluorescent
staining and confocal microscopy. A FITC-labelled pan-TLE
polyclonal antibody was used to detect the expression of endo-
genous TLE proteins; however, these experiments were not
conclusive as the expression of Myc–PRH in the nucleus hindered
detection of the endogenous TLE proteins (weak FITC signal)
in the cell. Therefore to address this question we next examined
the subcellular localization of endogenous TLE proteins using
subcellular fractionation and Western blot analysis. K562 cells or
K562 cells expressing Myc–PRH were fractionated into the post-
nuclear fraction consisting of cytoplasmic and loosely held nuc-
lear proteins and nuclear fractions consisting of tightly held
nuclear proteins. To compare the endogenous TLE protein levels
in each subcellular compartment an equal amount of protein from
each fraction was loaded on to SDS/PAGE and the TLE proteins
were detected using the pan-TLE antibody. Fractionation and
equal loading in each fraction was assessed by the expression of
tubulin in the post-nuclear fraction and lamin A/C in the nuclear
fraction. Figure 1(C) shows that endogenous TLE proteins were
predominantly localized to the post-nuclear fraction although a
faint band was present in the nuclear fraction (compare lanes 1
and 2). In contrast, in the presence of Myc–PRH, endogenous TLE
was strongly present in the nuclear fraction (Figure 1C, compare
lanes 3 and 4). The blot was stripped and reprobed with the Myc-
antibody to detect Myc–PRH. Myc–PRH was present in both the
post-nuclear and nuclear fractions (Figure 1C, lanes 3 and 4 lower
panel). We conclude that PRH increases the nuclear retention
of TLE proteins. Our previous immunofluoresence experiments
with Myc–PRH have shown that PRH is present in both the
nucleus and the cytoplasm [7]. This is in agreement with the frac-
tionation experiments presented in Figure 1. However PRH
localization in the presence of TLE appears strongly nuclear in
the immunofluorescence experiments shown above. This suggests
that co-expression of PRH with TLE has an influence on the
localization of PRH and vice versa.
TLE runs as a doublet on SDS/PAGE due to phosphorylation
[49]. The upper TLE band in Figure 1(C) (lane 4) very probably
corresponds to hyperphosphorylated TLE, and expression of PRH
brings about an increase in the intensity of this band suggesting
that PRH induces TLE phosphorylation (Figure 1C, compare
lane 1 with lane 4). To establish that the TLE proteins of retarded
mobility correspond to TLE phosphoproteins induced by PRH
expression, we incubated K562 nuclear extracts transfected with
Myc–PRH with CIP. There is a predominance of the TLE band
of retarded mobility (Figure 1D, lanes 1 and 2) after incubation
at 4 ◦C or 37 ◦C in the presence of a cocktail of phosphatase
inhibitors. Incubation of nuclear extracts with CIP in the absence
of phosphatase inhibitors resulted in a decrease in the intensity of
this upper band and an increase in intensity of the lower TLE
band (lanes 3 and 4). In contrast, incubation of the extracts with
CIP in the presence of phosphatase inhibitors does not lead to a
change in the TLE band (lane 5). These results show that the TLE
band of reduced mobility observed in the presence of Myc–PRH
corresponds to phosphorylated TLE.
Mutations in the PRH homeodomain block nuclear
relocalization of TLE
To investigate whether the DNA-binding and nuclear-localization
activities of PRH are required for the relocalization of TLE
proteins we designed two mutations in the Myc–PRH protein:
PRH N187A and PRH R188A,R189A. These mutations lie in the
homeodomain of the PRH protein and are shown in Figure 2(A).
The N187A mutation is predicted to significantly reduce the DNA-
binding activity of PRH since we have shown previously that
mutation of asparagine to alanine at the equivalent position in
the highly conserved avian PRH homeodomain prevents DNA
binding [6]. The R188A,R189A double mutation is predicted to
prevent the nuclear localization of PRH as mutation of these
arginine residues to alanine has been reported to block the nuclear
localization of PRH in NIH 3T3 cells [12]. To create these mut-
ations we performed site-directed mutagenesis of PRH in the ex-
pression plasmid pMUG1-Myc–PRH (as described in the
Experimental section). To check that the mutated Myc-tagged
PRH proteins were expressed at similar levels, K562 cells were
transfected with plasmids expressing Myc–PRH or each of the
mutant Myc–PRH proteins and cell extracts were produced.
Western blot analysis with the anti-Myc antibody and tubulin
antibodies showed that these proteins are expressed at equivalent
levels in K562 cells (Figure 2B).
To determine whether PRH proteins that carry these mutations
can alter the retention of TLE proteins, K562 cells or K562 cells
expressing Myc–PRH or the mutated proteins were fractionated
into nuclear and post-nuclear extracts. Equal amounts of total
protein from each fraction were loaded on to SDS/PAGE and
Western blotted with a pan-TLE antibody (Figure 3A, top panel)
or an anti-Myc antibody (Figure 3A, bottom panel). The blots
were stripped and reprobed for lamin A/C and tubulin to examine
fractionation quality and loaded as before. As expected, wild-type
PRH was able to alter the distribution of TLE proteins in each
fraction and to induce TLE hyperphosphorylation (Figure 3A,
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Figure 1 PRH alters the distribution of TLE proteins in the cell
(A) K562 cells were transiently transfected with vectors expressing FLAG–TLE1, FLAG–TLE1 and GFP–PRH or FLAG–TLE1 and GFP and then adhered to poly-lysine-coated coverslips. DNA
was stained with DAPI (blue). FLAG–TLE1 was visualized using an anti-FLAG antibody and a TRITC-labelled secondary antibody (red). GFP–PRH and GFP were visualized directly (green). The
cells were viewed using a Leica DM IRBE confocal microscope. (B) K562 cells were transiently transfected with vectors expressing FLAG–TLE1 or FLAG–TLE1 and Myc–PRH and then adhered
to poly-lysine-coated coverslips. DNA was stained with DAPI (blue). FLAG–TLE1 was visualized using an anti-FLAG antibody and a FITC-labelled secondary antibody (green). Myc–PRH was
visualized using an anti-Myc9E10 antibody and a TRITC-labelled secondary antibody (red). The cells were viewed using confocal microscopy as above. (C) Untransfected K562 cells and cells
transiently transfected with a vector expressing Myc–PRH were fractionated into post-nuclear (PN) and nuclear (Nuc) extracts. The proteins were then separated by SDS/PAGE and Western blotted
for endogenous TLE proteins using a pan-TLE antibody (top panel), lamin A/C using a rabbit polyclonal anti-lamin antibody (second panel), tubulin using a mouse monoclonal anti-tubulin antibody
(third panel) and Myc–PRH using an anti-Myc9E10 antibody (bottom panel). (D) K562 nuclear extracts from cells expressing Myc–PRH were incubated with a cocktail of phosphatase inhibitors in
CIP buffer for 30 mins at 4◦C (lane 1) or 37◦C (lane 2). In lanes 3 and 4, CIP was added to nuclear extracts without phosphatase inhibitors for 30 min at 37◦C [1 μl (lane 3) or 2 μl (lane 4)]. In
lane 5, CIP (2 μl) was added to nuclear extracts containing phosphatase inhibitors for 30 min at 37◦C.
compare lanes 1 and 5 with lanes 2 and 6). However both
mutant PRH proteins were unable to influence the distribution of
endogenous TLE (Figure 3A, top panel, lanes 7 and 8). Although
these results suggest that both the DNA-binding activity of PRH
and the nuclear localization of PRH are required in order to retain
nuclear TLE proteins, it is clear that the nuclear localization
mutant Myc–PRH R188A,R189A is present in both the post-
nuclear and nuclear extracts (Figure 3A, bottom panel).
To further examine the localization of the mutant PRH proteins
we used immunofluorescence microscopy. Figure 3(B) shows
high-magnification pictures of K562 cells stained with DAPI to
visualize the DNA (blue) and with TRITC (red) to visualize the
c© The Authors Journal compilation c© 2009 Biochemical Society
126 C. Desjobert and others
Figure 2 PRH mutants used in the present study
(A) A schematic representation of the PRH protein and the PRH mutants used in the present study. The Myc tag is represented by the filled box. The proline-rich domain and homeodomain (HD) are
indicated. (B) Whole-cell extracts were prepared from untransfected K562 cells (lane 1) and cells transiently transfected with vectors expressing Myc–PRH (lane 2), Myc–PRH R188A,R189A (lane 3),
Myc–PRH N187A (lane 4) or Myc–PRH F32E (lane 5). The proteins were then separated by SDS/PAGE and Western blotted for PRH using an anti-Myc9E10 antibody and a mouse monoclonal
anti-tubulin antibody as a control for protein loading.
PRH proteins. When the DAPI stain and the TRITC stain were
merged the cells appeared pink, demonstrating that wild-type
PRH and the mutant PRH proteins were present in the nucleus
of K562 cells. These results demonstrate that, in these cells,
PRH N187A and PRH R188A,R189A are able to localize in the
nucleus like wild-type PRH. We conclude that in K562 cells PRH
R188A,R189A are not defective in nuclear localization.
PRH R188A,R189A has a defect in DNA binding
We next investigated the DNA-binding properties of the mutated
proteins. The mutated PRH cDNAs present in the mammalian ex-
pression constructs were transferred to the pTrc-HisA bacterial
expression vector (see the Experimental section). The resulting
constructs inducibly express His-tagged mutated PRH proteins
in bacterial cells. Bacterial extracts expressing the mutated PRH
proteins or the wild-type protein were used to partially purify
His-tagged PRH proteins over a nickel-charged affinity column
and these partially purified proteins were used in EMSAs with
a labelled PRH-binding site as described previously [2,34].
Figure 3(C) shows that full length His–PRH was able to bind
to DNA in the EMSA and form two retarded DNA–PRH com-
plexes. In contrast, neither His–PRH N187A nor His–PRH
R188A,R189A form PRH–DNA complexes.
In summary, we have demonstrated that both PRH N187A
and PRH R188A,R189A can localize to the nucleus and that
they are both defective in DNA binding and influencing the
nuclear retention of TLE proteins. Since both mutations in the
homeodomain block DNA binding and the nuclear retention of
TLE proteins, but do not appear to significantly affect the nuclear
retention of PRH, we conclude that DNA binding by PRH is
necessary for the retention of TLE within the nucleus.
Mutation of the PRH Eh-1 motif blocks nuclear retention of TLE
To investigate whether the PRH–TLE interaction is required for
the nuclear retention of TLE proteins we examined the sub-
cellular distribution of TLE proteins in the presence of Myc–
PRH F32E (see Figure 2). A plasmid expressing Myc–PRH
F32E was produced in our previous study [7]. The PRH F32E
mutation was designed to inhibit the binding of PRH to TLE1.
This mutation lies in the N-terminal Eh-1 motif in PRH and
our previous studies have shown that this mutation eliminates
the interaction between TLE1 and the PRH N-terminal domain
[7]. K562 cells, or cells expressing Myc–PRH or Myc–PRH
F32E were fractionated and Western blotted as described above.
Figure 4(A) (top panel) shows that PRH F32E is unable to alter
the nuclear retention of endogenous TLE proteins (lanes 3 and 6).
These fractionation experiments also demonstrate that the mutant
PRH F32E protein is not altered in its ability to be retained
in the nucleus compared with wild-type PRH and is expressed
at a similar level to wild-type PRH (Figure 4A, bottom panel).
The mutant protein shows a slightly retarded mobility compared
with wild-type PRH (Figure 4A, bottom panel). The changed
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Figure 3 Mutations in the PRH homeodomain block nuclear retention of TLE
(A) Untransfected K562 cells and cells transiently transfected with vectors expressing Myc–PRH, Myc–PRH N187A or Myc–PRH R188A,R189A were fractionated into post-nuclear and nuclear
extracts. The proteins were then separated by SDS/PAGE and Western blotted for endogenous TLE (top panel), lamin A/C (second panel), tubulin (third panel) or Myc–PRH proteins (bottom panel)
as described in Figure 1(C). (B) K562 cells growing on coverslips were transiently transfected with vectors expressing Myc–PRH, Myc–PRH N187A or Myc–PRH R188A,R189A. DNA was stained
with DAPI (blue) and Myc–PRH was visualized using an anti-Myc9E10 antibody and a TRITC-labelled secondary antibody (red). The cells were viewed using a Leica DM IRBE confocal microscope.
(C) A labelled oligonucleotide carrying a PRH-binding site was incubated with increasing concentrations (125, 250 and 500 nM) of His-tagged PRH (lanes 1–3), His-tagged PRH R188A,R189A
(lanes 4–6), PRH N187A (lanes 7–9) and PRH F32E (lanes 10–12) under the conditions described in the main text. Free and bound DNA was then resolved on a 6 % polyacrylamide gel and visualized
using a PhosphoImager. Two retarded complexes (PRHC1 and PRHC2) are formed when PRH binds to the DNA.
mobility of the protein is also apparent in a fusion protein
consisting of GST (glutathione transferase) fused to the PRH
N-terminal domain carrying the F32E mutation [7]. The reason
for this apparent change in mobility is not known at present. We
confirmed that the nuclear localization of the PRH F32E was
not altered compared with wild-type PRH, using immunostaining
experiments and confocal microscopy (Figure 4B, middle panel).
Thus the F32E mutation in the Eh-1 domain of PRH does not
appear to alter nuclear localization of PRH but does block the
influence of PRH on the retention of TLE proteins.
To check that the DNA-binding properties of PRH are not
altered by the F32E mutation in the Eh-1 domain we transferred
the mutated PRH cDNA present in the mammalian expression
constructs to a bacterial expression vector downstream of a His-
tag. The His-tagged proteins were then partially purified and used
in EMSAs in parallel with the EMSA carried out previously for the
wild-type PRH protein and the PRH proteins carrying mutations in
the homeodomain. Figure 3(C) shows that PRH F32E was able to
bind DNA and formed the same PRH–DNA complexes as wild-
type PRH (compare lanes 3 and 12). Therefore the PRH F32E
mutation did not significantly alter the DNA-binding properties
of PRH.
The F32E mutation blocked the binding of the isolated PRH
N-terminal domain to TLE in pulldown experiments. To confirm
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Figure 4 Mutation of the PRH Eh-1 motif blocks the nuclear retention
of TLE
(A) Untransfected K562 cells and cells transiently transfected with vectors expressing Myc–PRH
or Myc–PRH F32E were fractionated into post-nuclear and nuclear extracts. The proteins were
then separated by SDS/PAGE and Western blotted for endogenous TLE (top panel), Myc–PRH
proteins (bottom panel), lamin A/C (second panel) or tubulin (third panel) as described in
Figure 1(C). (B) K562 cells growing on coverslips were transiently transfected with a vector
expressing Myc–PRH F32E. DNA was stained with DAPI (blue) and Myc–PRH F32E (red) was
visualized exactly as described in Figure 3(B). (C) Whole-cell extracts were prepared from K562
cells transiently co-transfected with a vector expressing FLAG–TLE1 and vectors expressing
Myc–PRH (lane 1), Myc–PRH R188A,R189A (lane 2), Myc–PRH N187A (lane 3) or Myc–PRH
F32E (lane 4). The Myc-tagged proteins were then immunoprecipitated using an anti-Myc9E10
antibody. The immunoprecipitated proteins were separated by SDS/PAGE and Western blotted
for PRH using an anti-Myc9E10 antibody (top panel) and co-immunoprecipitated TLE using an
anti-FLAG antibody (lower panel).
that the F32E mutation inhibited the binding of PRH to TLE in
the context of full-length PRH protein in vivo, we carried out
co-immunoprecipitation experiments with Myc-tagged PRH and
FLAG-tagged TLE1. Cell extracts were made from K562 cells
expressing Myc–PRH and FLAG–TLE1 or each of the mutant
Myc–PRH proteins and FLAG–TLE1 and immunoprecipitated
with an anti-Myc antibody bound to Protein G beads. After
extensive washing, the proteins were loaded on to SDS/PAGE and
Western blotted with the anti-Myc antibody to detect Myc–PRH,
and with a FLAG antibody to detect FLAG–TLE1. Figure 4(C)
(top panel) shows that the Myc-tagged PRH proteins were all im-
munoprecipitated by the anti-Myc antibody to approximately the
same extent. PRH and the PRH N187A and PRH R188A,R189A
mutants all co-immunoprecipitated FLAG-tagged TLE, whereas
PRH F32E failed to co-immunoprecipitate TLE (bottom panel).
These results demonstrate that the F32E mutation in the PRH Eh-
1 domain prevents the interaction of PRH and TLE in cells. In this
experiment the PRH N187A appears to immunoprecipitate much
more TLE than the corresponding wild-type PRH protein, which
may reflect an increased binding affinity between PRH N187A
and TLE proteins.
Repression by PRH requires retention of TLE proteins
in the nuclear fraction
In order to study the transcription repression properties of these
mutated PRH proteins, a reporter plasmid carrying the luciferase
gene under the control of the TK promoter and five PRH-binding
sites was transiently transfected into K562 cells with vectors
expressing PRH or the PRH mutants. In addition, all cells were
co-transfected with a plasmid expressing β-galactosidase to act as
a control for transient transfection efficiency. Figure 5(A) shows
that although PRH represses reporter activity to approx. 30% of
the unrepressed level, the DNA-binding-deficient mutants PRH
N187A and PRH R188A,R189A showed little or no repression
activity. In this assay PRH F32E was a very poor repressor and
had no more repression activity than the DNA-binding-defective
protein PRH N187A (Figure 5A, column 6). PRH is able to repress
transcription by several mechanisms, including binding to the
TATA box, and we have shown previously that at high expression
levels PRH F32E has some ability to repress transcription,
presumably via binding to the TATA box or because of residual
binding to TLE. In the present study we have directly compared
the repression activity of PRH F32E with that of wild-type
PRH, and Western blot analysis confirmed that in this assay the
proteins were expressed at equivalent levels in the transfected
cells (Figure 2B). We have demonstrated that PRH F32E does not
influence the retention of TLE proteins in the nucleus and that this
protein can bind to DNA such as wild-type PRH. We conclude
that the direct interaction between PRH and TLE is essential for
the enhanced nuclear retention of TLE proteins brought about by
PRH and plays an important role in transcriptional repression
by PRH.
PRH N187A is trans-dominant over PRH
The results presented above demonstrate that PRH N187A, PRH
R188A,R189A and PRH F32E are all defective in repression. In
order to further dissect the mechanisms whereby PRH represses
transcription, we next examined whether any of these mutant
PRH proteins would have a trans-dominant-negative activity over
transcriptional repression by wild-type PRH. The pTK–PRH
reporter plasmid described above was transfected into K562 cells
with plasmids expressing wild-type PRH and increasing amounts
of each of the plasmids expressing mutant PRH proteins. As
before, all cells were transfected with a plasmid expressing β-gal-
actosidase to control for transfection efficiency. Figure 5(B) shows
that, as expected, PRH repressed transcription to approx. 40% of
unrepressed promoter activity (lane 2). Increasing amounts
of PRH N187A (lanes 3–5), PRH F32E (lanes 9–11) or PRH
R188A,R189A (lanes 15–17) did not result in transcriptional
repression (as shown previously in Figure 5A); however, co-
expression of PRH with increasing amounts of PRH N187A
resulted in a significant decrease in repression by PRH (lanes 6–8)
and at a 2:1 ratio of PRH N187/PRH there was almost a complete
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Figure 5 PRH N187A is trans-dominant over PRH in transcription repression assays
The histograms show the relative promoter activity found in K562 cell extracts 24 h after transient co-transfection with a reporter plasmid containing the luciferase gene under the control of the TK
promoter and five PRH-binding sites (pTK–PRH), a β-galactosidase expression plasmid (pSV-lacZ) and PRH expression vectors. Relative promoter activity is the luciferase activity normalized with
respect to transfection efficiency using the co-transfected β-galactosidase plasmid. Each transfection was performed a minimum of three times and the values shown are the means +− S.D. (A) K562
cells were transfected with 5 μg of pTK–PRH alone (lane 1), pTK–PRH and 1 μg of an empty expression vector (lane 2), or pTK–PRH and 1 μg of pMUG1-PRH (lane 3), pMUG1-PRH R188A,R189A
(lane 4), pMUG1-PRH N187A (lane 5) or pMUG1-PRH F32E (lane 6). (B) K562 cells were transfected with 5 μg of pTK–PRH alone (lane 1), pTK–PRH and 1 μg of pMUG1-PRH (lane 2), or
pTK–PRH and increasing amounts (0.5, 1 and 2 μg) of the expressor plasmids indicated either with (filled bars) or without (empty bars) 1 μg of co-transfected pMUG1-PRH. (C) Whole-cell extracts
were prepared from untransfected K562 cells (lane 1) and cells transiently transfected with vectors expressing Myc–PRH F32E,N187A (lane 2), Myc–PRH F32E,R188A,R189A (lane 3) or Myc–PRH
(lane 4). The proteins were then separated by SDS/PAGE and Western blotted for PRH using an anti-Myc9E10 antibody. The membrane was stripped and reprobed with an anti-tubulin antibody as
a control for protein loading. (D) The experiment described in (B) was repeated using vectors expressing the PRH double mutants PRH F32E,N187A and PRH F32E,R188A,R189A. (E) K562 cells
were transiently transfected with vectors expressing FLAG–TLE1 and Myc–PRH or Myc-tagged PRH mutant proteins and then adhered to poly-lysine-coated coverslips. DNA was stained with DAPI
(blue). FLAG–TLE1 was visualized using an anti-FLAG antibody and a FITC-labelled secondary antibody (green). Myc–PRH was visualized using an anti-Myc9E10 antibody and a TRITC-labelled
secondary antibody (red). The cells were viewed using confocal microscopy. Co-localized proteins produce a yellow colour.
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loss of repression. In contrast, co-expression of PRH with increas-
ing amounts of PRH F32E (lanes 12–14) or PRH R188A,R189A
(lanes 18–20) did not alter the repression activity of PRH.
Thus these results demonstrate that PRH N187A has a trans-
dominant-negative activity over wild-type PRH for transcriptional
repression.
To investigate the mechanism of this trans-dominant inhibition
of PRH repression activity we used site-directed mutagenesis to
make two PRH expression plasmids that carried either a com-
bination of the F32E and N187A mutations or the F32E and
R188A,R189A mutations. K562 cells were transfected with the
reporter plasmid, the PRH expression vector and increasing
amounts of plasmids expressing these double mutants. Western
blot analysis confirmed that the double mutants were expressed
at equivalent levels to wild-type PRH (Figure 5C). Figure 5(D)
shows that PRH repressed transcription to approx. 30% of unre-
pressed promoter activity (lane 2) and that increasing amounts
of PRH F32E,N187A (lanes 3–5) or PRH F32E,R188A,R189A
(lanes 9–11) did not result in transcriptional repression. Co-
expression of PRH with increasing amounts of PRH F32E,N187A
(lanes 6–8) or PRH F32E,R188A,R189A (lanes 12–14) did not
result in a decrease in repression activity. Since PRH N187A has
trans-dominant negative activity but PRH F32E,N187A does not,
we infer that titration of TLE is essential for the trans-dominant-
negative activity of PRH N187A.
We have previously shown that Myc–PRH expression is
cytoplasmic and diffuse nuclear [7], and that the accumulation
of this protein in nuclear foci is apparent at lower levels of
expression [2]. We have also shown that co-expression of PRH
with FLAG–TLE1 protein results in their co-localization. Both
proteins show diffuse nuclear staining but, in addition, there is
co-localization in subnuclear foci [7]. To determine whether the
trans-dominant-negative protein PRH N187A is able to sequester
TLE proteins away from wild-type PRH and into a particular
subnuclear compartment we expressed FLAG–TLE1 protein in
K562 cells. The FLAG–TLE protein showed a diffuse nuclear
staining pattern (Figure 1A). We also expressed each of the Myc–
PRH proteins in K562 cells (Figures 3B and 4B) and these proteins
also showed diffuse nuclear staining. Interestingly, the co-
expression of Myc–PRH N187A and FLAG–TLE1 showed strong
co-localization of the two proteins in subnuclear foci (Figure 5E)
in immunofluorescent staining experiments (large yellow dots). In
contrast, the co-expression of TRITC-labelled Myc–PRH (wild-
type) or Myc–PRH F32E with FLAG–TLE1 resulted in co-
localization in the nucleus in a predominantly diffuse nuclear
staining pattern (Figure 5E). We conclude that the subnuclear
localization of PRH N187A and TLE1 are altered when the
proteins are co-expressed. Thus the interaction of PRH N187A
with TLE results in the sequestration of TLE in a subnuclear com-
partment that is not the same as the subnuclear compartment
occupied by wild-type PRH and TLE1. We infer that the inability
of PRH to bind to DNA prevents PRH N187A from taking TLE1 to
the DNA/chromatin or alternatively prevents TLE1 from taking
PRHN187A to the DNA/chromatin. In any event we conclude
that sequestration of TLE proteins to a different subnuclear
localization is involved in the trans-dominant-negative activity
of this protein.
DISCUSSION
PRH is a transcriptional repressor protein that plays important
roles in the regulation of several cellular processes including
haematopoiesis. PRH is present in both the cytoplasm and
nucleus of haematopoietic cells from myeloid lineages [7,27,31].
Aberrant expression of PRH or loss of nuclear localization of
PRH contributes to leukaemia [31]. K562 cells are blast cells
that can spontaneously differentiate along myeloid and erythroid
lineages. In the main, these cells contain a very large nucleus
and relatively little cytoplasm. Immunofluorescent staining of
PRH and TLE proteins in these cells has shown that PRH and
TLE can be present in both the nucleus and the cytoplasm [7].
We have used biochemical fractionation to examine the nuclear
retention of TLE proteins. We have shown that endogenous
nuclear TLE proteins are not tightly bound in the nuclei of K562
cells and fractionate into the post-nuclear fraction; however, in the
presence of exogenous PRH, endogenous TLE proteins become
strongly retained in the nuclear fraction. In other cell types the
Hes1 and Runx-1 repressor proteins have been shown to bind to
TLE and increase the nuclear retention of TLE by increasing the
association of TLE with chromatin [49]. Further experiments are
required to establish whether the mechanism of nuclear retention
of TLE in the presence of PRH is similar to that effected by
Hes1 and involves chromatin association of TLE proteins or other
subnuclear compartments such as the nuclear matrix.
The mutation of asparagine to alanine (N187A) in the DNA
recognition helix of the PRH homeodomain and mutation of
adjacent arginine residues (R188A,R189A) results in proteins
that are unable to bind to DNA. These mutants are both unable to
influence the nuclear retention of TLE proteins, although they are
able to bind to TLE. In fractionation studies both PRH N187A
and PRH R188A,R189A show both post-nuclear and nuclear
distribution. PRH N187A acts as a trans-dominant-negative
protein in repression assays with wild-type PRH. In contrast, PRH
R188A,R189A does not act as a trans-dominant-negative protein.
In the present study we have shown that PRH N187A and TLE
co-localize in subnuclear foci, whereas PRH R188A,R189A and
TLE do not co-localize in these foci. Presumably this difference
accounts for the trans-dominant repression activity of PRH
N187A; however the difference in the ability of these proteins to
have trans-dominant activity over wild-type PRH may be because
PRH N187A has a higher affinity for TLE or because the PRH
R188A,R189A has a subtle defect in nuclear retention. It is also
possible that the higher affinity of PRH N187A for TLE and/or
the subtle defect of PRH R188A,R189A in nuclear retention are
responsible for the difference in subnuclear localization. Finally
we cannot rule out the possibility that sequestration of TLE is
not wholly responsible for the trans-dominant-negative activity
of PRH N187A. PRH is known to form oligomers and it may be
that PRH N187A, but not the PRH R188A,R189A mutant, is able
to form hetero-oligomers with wild-type PRH and thereby block
repression. Interestingly, it is clear that in complete contrast with
previous reports, PRH R188A,R189A is able to enter the nucleus
of K562 cells, suggesting that this mutation does not strongly
affect the nuclear localization of PRH in these cells although this
mutation does inhibit the nuclear localization of PRH in NIH 3T3
cells [12]. One reason for this discrepancy could be that K562-
cell-specific proteins might aid the nuclear import of this mutant.
As might be expected, a mutation in the Eh1 motif (F32E)
located within the N-terminal domain of PRH reduces binding
to TLE and blocks nuclear retention of TLE. Thus the retention
of TLE proteins within the nucleus requires two properties of
the PRH protein: a direct protein–protein interaction between
PRH and TLE and DNA binding by PRH. Neither DNA binding
alone, nor TLE binding alone by PRH is sufficient for nuclear
retention of TLE or in fact for transcriptional repression by PRH.
Presumably the nuclear retention of TLE proteins is necessary for
transcriptional repression by PRH. We have reported previously
that although PRH F32E is defective in binding to TLE and
defective in repression compared with wild-type PRH, it retains
some repression activity when expressed at high levels. We
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suggest that this is because the mutant is not completely unable
to bind TLE and retains weak TLE-binding activity which may
become apparent at very high expression levels.
Since a defect in binding TLE blocks repression as effectively
as a defect in DNA binding, we conclude that most of the PRH-de-
pendent repression observed at the pTK–PRH promoter is TLE-
dependent; however, it is possible that mutation of the Eh-1
domain might also affect the conformation of the PRH protein
and hence also decrease the interaction of PRH with other PRH-
interacting proteins. The trans-dominant-negative activity of the
DNA-binding mutant PRH N187A together with the loss of this
trans-dominant-negative activity in the PRH F32E,N187A double
mutant (cannot bind to DNA and TLE) reinforces the idea that
transcriptional repression is very sensitive to the availability of
TLE. PRH N187A may prove to be a useful tool for understand-
ing the direct and indirect transcriptional activities of PRH.
Clearly the ability of PRH N187A to act as a trans-dominant
negative for PRH repression activity occurs through a very
different mechanism from that inferred for the trans-dominant-
negative activity of a Nup–Hex/PRH fusion protein identified
recently in a patient with acute myeloid leukaemia. In the Nup–
Hex/PRH fusion protein, the N-terminus of the nucleoporin
protein Nup98 is fused in-frame with the homeodomain and
C-terminus of PRH. In this case the N-terminus (TLE-binding
region) of PRH is absent in the fusion protein and it is thought that
the trans-dominant-negative function of Nup–Hex/PRH derives
from the ability of the fusion protein to compete with PRH for
PRH-binding sites [32]. The experiments outlined above demon-
strate that there is more than one way to block PRH repression
activity and suggest that acute myeloid leukaemic patients might
harbour a variety of PRH mutations.
We have shown in the present study that PRH directly affects
nuclear retention of TLE and presumably, as a consequence,
availability of TLE in discrete subnuclear domains. Thus it is very
likely that TLE-dependent genes may be equally sensitive to PRH
levels. Further work is required to determine whether alterations
in PRH expression impact on the plethora of TLE-repressed genes
that do not appear to contain binding sites for PRH. Our studies
have shown that PRH can influence the amount of available TLE
proteins in the nucleus; however, it is not known whether binding
of TLE to PRH results in PRH sequestering TLE away from
other transcription factors in the nucleus or whether PRH simply
increases the amount of free TLE proteins in the nucleus. The Wnt
signalling pathway functions in haematopoietic progenitors to
promote self renewal [52]. TLE proteins are important antagonists
for Wnt signalling [53,54]. The Notch signalling pathway also
functions in haematopoietic progenitors to inhibit differentiation
along myeloid lineages and thereby increase the amount of
undifferentiated progenitors [55,56]. TLE proteins mediate the
Notch signalling pathway and thereby promote the inhibition of
differentiation [55,56]. Thus an increase in available TLE in the
nucleus might be expected to inhibit self renewal and decrease
differentiation. Interestingly PRH functions as an inhibitor of
cell proliferation in early haematopoietic progenitors and in dif-
ferentiated myeloid cells. Although the effect of PRH on cell
proliferation has been shown to be through the regulatory effect
of PRH on the translation factor eIF-4E [12], the anti-proliferative
effects of PRH could also be a consequence of PRH altering the
amount of available nuclear TLE.
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